Neurology Central

Emgality® achieves primary and secondary outcomes in Phase III trial for migraines


Eli Lilly and Company (Basingstoke, UK) have announced that Emgality® (galcanezumab) has met the primary and all key secondary outcomes in a Phase III clinical trial evaluating the efficacy and safety of the drug (the CONQUER study).

CONQUER was a Phase III, double-blind, global study conducted in 12 countries, which enrolled 462 people with chronic migraine (n = 193) or episodic migraine (n = 269) who had a documented history of treatment failures on two to four different standard-of-care migraine preventive medication categories.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.